Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anhui Medical Univ. hCA II compound 3o
- Development stage
- Unknown
- Lead developer
- Anhui Medical University
01
Overview
Anhui Medical Univ. hCA II compound 3o: sourced facts only. name: "Among them, compounds 3o and 3h showed excellent inhibitory activity against hCA II, with Ki values of 1.65 nM and 2.26 nM, respectively, while compounds such as 3e also demonstrated certain selectivity among different hCA isoforms." [PMID:41579812]; target: "Among them, compounds 3o and 3h showed excellent inhibitory activity against hCA II, with Ki values of 1.65 nM and 2.26 nM, respectively, while compounds such as 3e also demonstrated certain selectivity among different hCA isoforms." [PMID:41579812]; developer: "Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, PR China." [PMID:41579812]
02
Targets
CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on Anhui Medical Univ. hCA II compound 3o.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anhui Medical Univ. hCA II compound 3o.